Strategic Acquisition AngioScore was acquired by Spectranetics for $230M in 2014, indicating a credible exit and potential for integrated sales channels or cross-selling of interoperability solutions to extended customer bases.

Market Footprint With 51-200 employees and a Fremont, California base, AngioScore operates in a niche medical device segment, suggesting a focused, relationship-driven sales approach targeting vascular intervention labs and hospitals adopting new plaque scoring technologies.

Product-Market Fit The AngioSculpt Scoring Balloon catheter addresses both peripheral and coronary artery disease, signaling opportunities to position the device for multi-territory sales within existing accounts that treat diverse vascular lesions.

Revenue Scope Reported revenue in the $10M–$25M range indicates a proven but growing revenue stream, presenting upsell opportunities to expand adoption within current customers and to expand distribution through larger legacy device networks.

Key Relationships Past leadership hires and strategic moves (such as consultant acquisitions) imply a willingness to engage with specialized experts; leverage clinical KOLs and targeted field reps to accelerate adoption and secure favorable procurement decisions.